Clinical Trial Update: Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating the triple combination of ivosidenib, nivolumab, and ipilimumab in previously treated nonresectable or metastatic IDH1-mutant chola…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• OPDIVO (nivolumab)
• Tibsovo (ivosidenib)
• Yervoy (ipilimumab)

Snippet

Sponsor: Servier Bio-Innovation LLC | Conditions: IDH1-mutant Cholangiocarcinoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2026-02-12